Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Eli Lilly assures investors it can overcome the high-quality problem of too much demand

10 Most Promising Stocks to Buy Before They Take Off

Oppenheimer Remains a Buy on Biogen (BIIB)

Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)

Biogen’s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating

Decoding Biogen Inc (BIIB): A Strategic SWOT Insight

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript

Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year

Stock Market News for Apr 25, 2024